Nearly 100 bipartisan House members (led by Reps. Matsui, Johnson, Dingell, and Mann) sent a letter to HRSA urging that no federal funds be used to implement a 340B rebate model. This follows HRSA’s Request for Information (RFI) on whether to revive the pilot program that was halted following a federal court injunction in early 2026. The timing and breadth of the congressional response signal a rare moment of bipartisan agreement: the rebate model is fundamentally problematic for the covered entities and patients the 340B program was designed to protect.
What Congress is Actually Saying
The bipartisan letter signals something rarely seen in health policy: consensus across party lines on a complex regulatory issue. Signatories include both progressive Democrats and conservative Republicans, united by a common concern: federal funding should not be used to undermine a program that serves Ryan White clinics, Medicaid-funded safety net providers, and other covered entities. This congressional pressure adds significant weight to the extensive opposition already filed by covered entity coalitions, patient advocacy groups, and policy organizations.
The 4th Circuit Adds More Complexity
Meanwhile, the legal landscape is shifting. The 4th Circuit Court of Appeals upheld a block on West Virginia’s 340B contract pharmacy protection law, ruling that it is likely preempted by federal law. This ruling, combined with similar legal challenges in North Dakota, Washington State, and Indiana, creates a paradoxical situation: while Congress is pushing back against the federal rebate model, drug manufacturers are simultaneously challenging state-level protections of 340B access. The net effect is a narrowing corridor for covered entity revenue protection.
What This Means for Your Organization
The combination of rebate model uncertainty at the federal level plus escalating state law battles creates a 340B landscape that is harder to predict than at any point in the last decade. Organizations that have relied on 340B savings are now operating in an uncertain environment. A policy shift in either direction—whether HRSA moves forward with a rebate model, manufacturers succeed in preempting state protections, or both—could significantly impact revenue, and this is unfortunately not a temporary situation.
How PIAP Creates a Buffer
By investing 340B savings into a Premium Insurance Assistance Program (PIAP), covered entities create a secondary revenue stream that is fundamentally different from 340B-dependent income. When PIAP-enrolled patients receive healthcare services from commercial insurers, the organization generates commercial reimbursements: revenue that flows directly from insurance claims, not from drug pricing arrangements. This revenue stream is unaffected by typical policy changes, and these patients receive care and continue generating value for your organization.
American Exchange helps covered entities and Ryan White providers design PIAP programs that keep patients insured even when policies change. fall short. Contact us to learn how PIAP can protect your patients and strengthen your organization.
Sources
Bipartisan House Letter on 340B Rebate Mode – America’s Essential Hospitals Coalition
4th Circuit Upholds Block on West Virginia 340B Law, Rules Federal Preemption – AHA News
Trump Administration 2027 Budget Proposal and Impact on 340B – Modern Healthcare
